Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic.
Pineda-Peña AC, Schrooten Y, Vinken L, Ferreira F, Li G, Trovão NS, Khouri R, Derdelinckx I, De Munter P, Kücherer C, Kostrikis LG, Nielsen C, Littsola K, Wensing A, Stanojevic M, Paredes R, Balotta C, Albert J, Boucher C, Gomez-Lopez A, Van Wijngaerden E, Van Ranst M, Vercauteren J, Vandamme AM, Van Laethem K. Pineda-Peña AC, et al. Among authors: van laethem k, van wijngaerden e, van ranst m. PLoS One. 2014 Jul 8;9(7):e101738. doi: 10.1371/journal.pone.0101738. eCollection 2014. PLoS One. 2014. PMID: 25003369 Free PMC article.
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations.
Van Laethem K, Van Vaerenbergh K, Schmit JC, Sprecher S, Hermans P, De Vroey V, Schuurman R, Harrer T, Witvrouw M, Van Wijngaerden E, Stuyver L, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM. Van Laethem K, et al. Among authors: van vaerenbergh k, van wijngaerden e, van ranst m. J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):107-18. doi: 10.1097/00126334-199910010-00001. J Acquir Immune Defic Syndr. 1999. PMID: 10843523
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
Van Laethem K, Schmit JC, Pelemans H, Balzarini J, Witvrouw M, Pérez-Pérez MJ, Camarasa MJ, Esnouf RM, Aquaro S, Cenci A, Perno CF, Hermans P, Sprecher S, Ruiz L, Clotet B, Van Wijngaerden E, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM. Van Laethem K, et al. Among authors: van wijngaerden e, van ranst m. AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):825-33. doi: 10.1089/08892220050042765. AIDS Res Hum Retroviruses. 2000. PMID: 10875608
Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.
Van Vaerenbergh K, Debaisieux L, De Cabooter N, Declercq C, Desmet K, Fransen K, Maes B, Marissens D, Miller K, Muyldermans G, Sprecher S, Stuyver L, Vaira D, Verhofstede C, Zissis G, Van Ranst M, De Clercq E, Desmyter J, Vandamme AM. Van Vaerenbergh K, et al. Among authors: van ranst m. Antivir Ther. 2001 Mar;6(1):63-70. Antivir Ther. 2001. PMID: 11417763
Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J.
Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, Van Laethem K, Van Vaerenbergh K, Snoeck J, Van Wijngaerden E, De Clercq E, Van Ranst M, Vandamme AM. Fontaine E, et al. Among authors: van laethem k, van vaerenbergh k, van wijngaerden e, van ranst m. J Acquir Immune Defic Syndr. 2001 Nov 1;28(3):254-8. doi: 10.1097/00042560-200111010-00008. J Acquir Immune Defic Syndr. 2001. PMID: 11694832
Lack of evidence for infection with simian immunodeficiency virus in bonobos.
Van Dooren S, Switzer WM, Heneine W, Goubau P, Verschoor E, Parekh B, De Meurichy W, Furley C, Van Ranst M, Vandamme AM. Van Dooren S, et al. Among authors: van ranst m. AIDS Res Hum Retroviruses. 2002 Feb 10;18(3):213-6. doi: 10.1089/08892220252781275. AIDS Res Hum Retroviruses. 2002. PMID: 11839156 No abstract available.
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients.
Van Vaerenbergh K, Harrer T, Schmit JC, Carbonez A, Fontaine E, Kurowski M, Grünke M, Löw P, Rascu A, Schmidt B, Schmitt M, Thoelen I, Walter H, Van Laethem K, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM. Van Vaerenbergh K, et al. Among authors: van laethem k, van ranst m. AIDS Res Hum Retroviruses. 2002 Apr 10;18(6):419-26. doi: 10.1089/088922202753614182. AIDS Res Hum Retroviruses. 2002. PMID: 11958685
461 results